BofA Securities Downgrades Moderna (MRNA) to Underperform; Hard to Justify Run
Tweet Send to a Friend
(Updated - February 1, 2021 6:36 AM EST)BofA Securities analyst Geoff Meacham downgraded Moderna (NASDAQ: MRNA) from Neutral to Underperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
